News
Media
Puzzler
Publications
CME/CE
Resources
Conferences
Partnerships
Subscribe
Editorial

|Videos|April 5, 2022

Dr. Amy Paller discusses long-term safety and efficacy of ixekizumab in kids

Author(s)Miranda Hester

Dr. Paller discusses the findings of the clinical trial examining the long-term effects of ixekizumab for treating psoriasis in children.

Dr. Paller discusses the findings of the clinical trial discussing the long-term effects of ixekizumab for treating psoriasis in children.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Related Content

FDA approves Waskyra as first gene therapy for Wiskott-Aldrich syndrome | Image credit: Contemporary Pediatrics

FDA approves Waskyra as first gene therapy for Wiskott-Aldrich syndrome

ByJoshua Fitch, Senior Editor

December 10th 2025

FDA approves omidubicel-onlv as first HSCT therapy to treat severe aplastic anemia | Image credit: Contemporary Pediatrics

FDA approves omidubicel-onlv as first HSCT therapy to treat severe aplastic anemia

ByJoshua Fitch, Senior Editor

December 8th 2025

ASH data: Marstacimab improves bleeding outcomes in adolescents, adults with hemophilia A or B | Image Credit: © jarun011 - © jarun011 - stock.adobe.com.

ASH data: Marstacimab improves bleeding outcomes in adolescents, adults with hemophilia A or B

ByJoshua Fitch, Senior Editor

December 8th 2025

FDA expands indication for MED-EL cochlear implants to infants 7 months and older | Image credit: Contemporary Pediatrics

FDA expands indication for MED-EL cochlear implants to infants 7 months or older

ByMorgan Ebert, Managing Editor

December 4th 2025

New analysis highlights nirsevimab as most impactful RSV prevention strategy for infants | Image Credit: © Sukjai Photo - stock.adobe.com.

New analysis highlights nirsevimab as most impactful RSV prevention strategy for infants

ByMorgan Ebert, Managing Editor

December 3rd 2025

Latest CME

Community Practice Connections™: Cases and Conversations – Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis

Community Practice Connections™: Cases and Conversations – Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis

Frank B. Cortazar, MD; Lindsay S. Lally, MD

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

In-Person + Virtual Event

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

January 23, 2026

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP; Anders Carlson, MD; Jennifer B. Green, MD

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

Trending on Contemporary Pediatrics

FDA approves Waskyra as first gene therapy for Wiskott-Aldrich syndrome

Vaccines in childhood linked to lower drug-resistant bacteria risk

Review finds no systemic risks from aluminum in childhood vaccines

Joshua Feder, MD, on presenting DRBIs, NDBIs, as options in addition to applied behavioral analysis

Full case: A slender teen with a growing abdomen and shrinking height velocity

© 2025 MJH Life Sciences^®

All rights reserved.